Corticosteroids for HELLP syndrome in pregnancy.

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Pharmacology in Pregnancy

Background:

• HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) is a severe pregnancy complication linked to pre-eclampsia.
• It significantly increases maternal and perinatal morbidity and mortality, often presenting before term.
• Observational studies suggest corticosteroids may improve hematological/biochemical features and perinatal outcomes.

Purpose of the Study:

• To systematically review evidence on corticosteroid efficacy in reducing maternal and neonatal mortality and morbidity in HELLP syndrome.
• To evaluate the impact of steroid therapy on key clinical outcomes in affected pregnancies.

Main Methods:

• Searched the Cochrane Pregnancy and Childbirth Group trials register and reference lists for relevant studies.
• Included randomized and quasi-randomized trials of adjunctive corticosteroids for diagnosed HELLP syndrome.
• Independent data extraction and quality assessment by two authors.

Main Results:

• Five studies (n=170) were reviewed; four compared dexamethasone to standard therapy.
• Dexamethasone showed no significant difference in primary maternal/perinatal mortality or major morbidity outcomes.
• Dexamethasone was associated with shorter hospital stays, a tendency for increased platelets, and higher birthweight compared to controls.

Conclusions:

• Insufficient evidence exists to confirm if adjunctive steroid use in HELLP syndrome reduces maternal and perinatal mortality or major morbidity.
• Further high-quality randomized trials are needed to clarify the role of corticosteroids in managing HELLP syndrome.